Actaviaa Biotech Profile
Key Indicators
- Authorised Capital ₹ 12.10 Cr
as on 05-07-2024
- Paid Up Capital ₹ 11.48 Cr
as on 05-07-2024
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 26.50 Cr
as on 05-07-2024
- Revenue -99.60%
(FY 2023)
- Profit -81.89%
(FY 2023)
- Ebitda -67.48%
(FY 2023)
- Net Worth -0.88%
(FY 2023)
- Total Assets 5.02%
(FY 2023)
About Actaviaa Biotech
The Corporate was formerly known as Actavia Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 12.10 Cr and a paid-up capital of Rs 11.48 Cr.
The company currently has active open charges totaling ₹26.50 Cr.
The Key Managerial Personnel (KMP) at Actaviaa Biotech Private Limited India is Sujata Pal as COMPANY SECRETARY. Sameer Goel, Vipul Goel, and Deepa Goel serve as directors at the Company.
- CIN/LLPIN
U24239DL2019PTC385590
- Company No.
067046
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Nov 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Actaviaa Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sujata Pal | Company Secretary | 27-Jun-2024 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sameer Goel  | Director | 22-Jun-2021 | Current |
| Vipul Goel | Director | 18-Nov-2019 | Current |
| Deepa Goel | Additional Director | 02-Jan-2024 | Current |
Financial Performance of Actaviaa Biotech.
Actaviaa Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 99.6% decrease. The company also saw a substantial fall in profitability, with a 81.89% decrease in profit. The company's net worth dipped by a decrease of 0.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Actaviaa Biotech?
In 2023, Actaviaa Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Zeneses Biosciences Private LimitedActive 21 years 22 days
Sameer Goel and Vipul Goel are mutual person
- Biowia Biotech Private LimitedActive 1 year 11 months
Sameer Goel, Vipul Goel and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 12 Apr 2023 | ₹26.50 Cr | Open |
How Many Employees Work at Actaviaa Biotech?
Unlock and access historical data on people associated with Actaviaa Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Actaviaa Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Actaviaa Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
